Company intelligence / Profile preview
Crossignal Therapeutics
La Jolla, California, United Statescrossignaltherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Crossignal Therapeutics develops a new generation of small molecule immunotherapies targeting immune cell-expressed tumor metabolic factor GPCRs to overcome cancer immune escape. Their lead asset CT3001 targets GPR35 and has entered Phase 1/2 clinical trials for advanced solid tumors. Additional programs include adenosine receptor antagonists and early-stage discovery efforts leveraging their proprietary PPS assay platform. The company holds full IP and global commercial rights to its assets.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesChemical drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Crossignal Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Crossignal Therapeutics.